Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Stock Watch - Oncimmune - Oncimmune yesterday won funding from the Government to develop a ... https://thismon.ee/a/8812545?ito=twitter_share_article-factbox via @ThisIsMoney
The IMPACTT programme will collect samples and data from 3,000 UK #COVID19 patients to be studied by @OncimmuneECDT to develop and validate an Infectious Disease NavigAID™ panel of biomarkers that can be used in research.
Read the full press release > http://ow.ly/TLEk50BLI3p
"Earlier diagnosis of #cancer can be
transformative of peoples lives, and we need to
continue to undertake the planning and research to
achieve it." Professor Chris Witty @CR_UK @UK_ABHI @BVDAPresse
Oncimmune/Medicines Discovery Catapult win UK government funding for COVID-19 research tool http://dlvr.it/Rj3nJX
“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, @AlokSharma_RDG
@beisgovuk @UKRI_News @DHSCgovuk @innovateuk
https://md.catapult.org.uk/news/oncimmune-and-medicines-discovery-catapult-awarded-uk-government-funding-for-development-of-an-infectious-disease-research-tool-for-use-in-covid-19/
#COVID19 #autoantibodies
'@OncImmuneECDT is creating a research tool to help choose the best treatments for coronavirus patients. using @InnovateUK funding from the UKRI COVID-19 open call #TacklingCoronavirus https://twitter.com/OncimmuneECDT/status/1313363433434251264
We are delighted to be be partnering with @MedDiscCat on this project. "This in turn will help us better target treatments and improve outcomes for all patients, to protect those most at risk from coronavirus."@MattHancock @DHSCgovuk @UKRI_News @innovateuk https://oncimmune.com/our-campaign/oncimmune-joins-fight-against-covid-19
Private cancer #screening services for bowel, breast, skin, prostate, cervical & lung #cancer. We also offer cancer #diagnostic & cancer #genetic investigations, clinics across the UK, find out more here http://bit.ly/32Qw9Qw
#check4cancer
Gallery
